Rani Therapeutics (RANI) grants 2M stock options to its CFO

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. reports that its Chief Financial Officer, Nicholas Maestas, received a compensation grant of a stock option on July 17, 2026 covering 2,000,000 shares of Class A common stock at an exercise price of $0.6973 per share. The option expires on July 16, 2036. According to the vesting terms, 25% of the shares vest on June 29, 2027, and 1/48th of the shares vest monthly over the following three years, subject to his Continuous Service under the company’s 2026 Inducement Plan. Following this award, Maestas holds options for 2,000,000 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Maestas Nicholas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	2,000,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,000,000 shares (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 29, 2027; and 1/48th of the shares subject to the option vest monthly thereafter over the remaining three years, subject to the Reporting Person's Continuous Service (as defined in the Company's 2026 Inducement Plan) through each such vesting date.

Key Figures

Options granted: 2,000,000 shares Exercise price: $0.6973 per share Expiration date: 2036-07-16 +4 more

7 metrics

Options granted 2,000,000 shares Stock Option (Right to Buy) granted to CFO on 2026-07-17

Exercise price $0.6973 per share Conversion or exercise price of the granted stock option

Expiration date 2036-07-16 Option expires roughly 10 years after grant

Transaction price per share $0.0000 Compensation grant with no cash paid per option at grant

Underlying shares 2,000,000 shares Class A Common Stock underlying the stock option

Post-grant option holdings 2,000,000 options Total options held by CFO following the reported transaction

Initial vesting date June 29, 2027 25% of the option vests on this date, subject to Continuous Service

Key Terms

Stock Option (Right to Buy), Class A Common Stock, Continuous Service, 2026 Inducement Plan, +1 more

5 terms

Stock Option (Right to Buy) financial

"Security title is listed as "Stock Option (Right to Buy)" for the grant"

Class A Common Stock financial

"The underlying security title is identified as Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Continuous Service financial

"Vesting is subject to the Reporting Person's Continuous Service through each vesting date"

2026 Inducement Plan financial

"Continuous Service is defined in the Company's 2026 Inducement Plan"

vest monthly financial

"1/48th of the shares subject to the option vest monthly thereafter"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/21/2026 - 04:51 PM Accepted by SEC EDGAR 07/21/2026 - 04:51 PM Learn about SEC filing dates

FAQ

What insider transaction did Rani Therapeutics (RANI) disclose for its CFO?

Rani Therapeutics disclosed that CFO Nicholas Maestas received a grant of 2,000,000 stock options for Class A common stock. The award is a compensation-related option grant, not an open-market share purchase or sale.

How many stock options did the RANI CFO receive and at what exercise price?

CFO Nicholas Maestas was granted 2,000,000 stock options with an exercise price of $0.6973 per share. These options give him the right to buy Class A common stock at that price if and when they vest.

What is the vesting schedule for the Rani Therapeutics (RANI) CFO’s new options?

The option vests 25% on June 29, 2027, with the remaining shares vesting at 1/48 per month over the next three years. Vesting requires Maestas to maintain Continuous Service through each vesting date.

When do the newly granted RANI CFO stock options expire?

The stock options granted to CFO Nicholas Maestas expire on July 16, 2036. After that date, any unexercised portion of the option can no longer be used to purchase Class A common shares.

How many options does the Rani Therapeutics (RANI) CFO hold after this grant?

After this reported grant, CFO Nicholas Maestas holds 2,000,000 stock options for Rani Therapeutics’ Class A common stock. This figure reflects the total number of options reported following the transaction.

Is the RANI CFO’s option grant tied to the company’s 2026 Inducement Plan?

Yes. The footnote states that vesting is subject to the CFO’s Continuous Service as defined in Rani Therapeutics’ 2026 Inducement Plan, linking the award’s terms directly to that plan’s provisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maestas Nicholas

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.6973	07/17/2026		A		2,000,000		(1)	07/16/2036	Class A Common Stock	2,000,000	$0	2,000,000	D

Explanation of Responses:

1. The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 29, 2027; and 1/48th of the shares subject to the option vest monthly thereafter over the remaining three years, subject to the Reporting Person's Continuous Service (as defined in the Company's 2026 Inducement Plan) through each such vesting date.

	/s/ Carlos Perez, Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)